89 related articles for article (PubMed ID: 10918510)
1. Summaries of round-table discussions.
Hum Exp Toxicol; 2000 Apr; 19(4):213-8. PubMed ID: 10918510
[No Abstract] [Full Text] [Related]
2. Lack of carcinogenicity of daminozide, alone or in combination with its contaminant 1,1-dimethylhydrazine, in a medium-term bioassay.
Cabral R; Hakoi K; Hoshiya T; Hasegawa R; Ito N
Teratog Carcinog Mutagen; 1995-1996; 15(6):307-12. PubMed ID: 8732881
[TBL] [Abstract][Full Text] [Related]
3. The clinical significance of beryllium.
Aller AJ
J Trace Elem Electrolytes Health Dis; 1990 Mar; 4(1):1-6. PubMed ID: 2135953
[TBL] [Abstract][Full Text] [Related]
4. Characterization of immunotherapeutic agents: the example of imuthiol.
Renoux G
Methods Find Exp Clin Pharmacol; 1986 Jan; 8(1):45-50. PubMed ID: 3010014
[TBL] [Abstract][Full Text] [Related]
5. Preclinical assessments of european union marketing authorisation applications for immunomodulatory biopharmaceuticals.
Liminga U
Hum Exp Toxicol; 2000 Apr; 19(4):257-60. PubMed ID: 10918519
[TBL] [Abstract][Full Text] [Related]
6. Aluminium-adjuvanted vaccines--a review of the current state of knowledge.
Gołoś A; Lutyńska A
Przegl Epidemiol; 2015; 69(4):731-4, 871-4. PubMed ID: 27139352
[TBL] [Abstract][Full Text] [Related]
7. Safety evaluation of immunomodulatory biopharmaceuticals: can we improve the predictive value of preclinical studies?
Black LE; Green JD; Rener J; Dayan A; Cavagnaro JA; Spindler P; Bussiere JL; Bouchard P; Inoue T; Thomas PT; Essayan DM; Gillett NA; Hart TK; Hastings K; House RV; Latta D; Liminga U; Treacy G; Wierda D
Hum Exp Toxicol; 2000 Apr; 19(4):205-7. PubMed ID: 10918508
[No Abstract] [Full Text] [Related]
8. [Anticarcinogenic effect of palustran on development of tumors induced by 3-(1-alpha-L-arabinopyranosyl)-1-methyl-1-nitrosourea (AMNU) in rats].
Sherenesheva NI; Fin'ko VE; Blanko FF; Alieva TA; Bedrina EN; Gogoleva IA; Klochkova TI
Biull Eksp Biol Med; 1998 May; 125(5):566-8. PubMed ID: 9644561
[No Abstract] [Full Text] [Related]
9. Stearyl tyrosine. An organic equivalent of aluminum-based immunoadjuvants.
Penney C
Pharm Biotechnol; 1995; 6():611-24. PubMed ID: 7551239
[No Abstract] [Full Text] [Related]
10. The 2nd NIEHS Predictive-Toxicology Evaluation Experiment: 30 chemical carcinogenicity bioassays.
Environ Health Perspect; 1996 Oct; 104 Suppl 5():999-1112. PubMed ID: 9036020
[No Abstract] [Full Text] [Related]
11. IABS international scientific workshop--Mode of Action of Adjuvants: implications for vaccine safety and design, April 29-30, 2010, Bethesda, MD, USA.
Seemann S; Dodet B
Vaccine; 2011 Apr; 29(17):3340. PubMed ID: 21335035
[No Abstract] [Full Text] [Related]
12. When an aluminium adjuvant is not an aluminium adjuvant used in human vaccination programmes.
Exley C
Vaccine; 2012 Mar; 30(12):2042. PubMed ID: 22041301
[No Abstract] [Full Text] [Related]
13. A need for effective adjuvants.
Bunce CJ; Morse MA
Curr Opin Mol Ther; 2003 Feb; 5(1):8-9. PubMed ID: 12669464
[No Abstract] [Full Text] [Related]
14. Short-and medium-term carcinogenicity tests: simple initiation-promotion assay systems.
Tsuda H; Park CB; Moore MA
IARC Sci Publ; 1999; (146):203-49. PubMed ID: 10353389
[No Abstract] [Full Text] [Related]
15. Mouse-specific carcinogens: an assessment of hazard and significance for validation of short-term carcinogenicity bioassays in transgenic mice.
Battershill JM; Fielder RJ
Hum Exp Toxicol; 1998 Apr; 17(4):193-205. PubMed ID: 9617631
[TBL] [Abstract][Full Text] [Related]
16. Methyl tertiary butyl ether (MTBE)--evaluation of MTBE carcinogenicity studies.
Rudo KM
Toxicol Ind Health; 1995; 11(2):167-73. PubMed ID: 7491632
[No Abstract] [Full Text] [Related]
17. Are tumor incidence rates from chronic bioassays telling us what we need to know about carcinogens?
Gaylor DW
Regul Toxicol Pharmacol; 2005 Mar; 41(2):128-33. PubMed ID: 15698536
[TBL] [Abstract][Full Text] [Related]
18. Immunomodulative effects of aflatoxins and selenium on human peripheral blood lymphocytes.
Methenitou G; Maravelias C; Koutsogeorgopoulou L; Athanaselis S; Koutselinis A
Vet Hum Toxicol; 1996 Aug; 38(4):274-7. PubMed ID: 8829345
[TBL] [Abstract][Full Text] [Related]
19. The use of genetically modified animals in carcinogenicity bioassays.
Maronpot RR
Toxicol Pathol; 2000; 28(3):450-3. PubMed ID: 10862565
[No Abstract] [Full Text] [Related]
20. Animal studies in potency ranking of carcinogens in Norway.
Sanner T; Dybing E; Hardeng S; Haug E; Ovrebø S
Prog Clin Biol Res; 1992; 374():399-414. PubMed ID: 1620715
[No Abstract] [Full Text] [Related]
[Next] [New Search]
